Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.

Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.